Nuvalent (NASDAQ:NUVL) Insider Sells $412,247.52 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Christopher Durant Turner sold 4,236 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the completion of the sale, the insider owned 58,311 shares in the company, valued at $5,674,826.52. This represents a 6.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Christopher Durant Turner also recently made the following trade(s):

• On Tuesday, January 6th, Christopher Durant Turner sold 3,181 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total value of $309,065.96.

Nuvalent Stock Up 9.9%

NASDAQ:NUVL traded up $9.62 on Wednesday, reaching $106.82. 895,694 shares of the company’s stock were exchanged, compared to its average volume of 779,373. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32. Nuvalent, Inc. has a 52-week low of $55.53 and a 52-week high of $112.88. The business has a fifty day moving average of $102.57 and a 200-day moving average of $88.78.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same quarter last year, the firm earned ($1.28) EPS. As a group, equities analysts anticipate that Nuvalent, Inc. will post -3.86 earnings per share for the current year.

Institutional Investors Weigh In On Nuvalent

Several hedge funds and other institutional investors have recently made changes to their positions in NUVL. Vanguard Group Inc. lifted its stake in Nuvalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 4,605,007 shares of the company’s stock worth $398,241,000 after purchasing an additional 80,883 shares during the last quarter. Wellington Management Group LLP increased its stake in Nuvalent by 46.0% in the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares during the last quarter. State Street Corp raised its holdings in Nuvalent by 4.2% during the second quarter. State Street Corp now owns 1,490,279 shares of the company’s stock worth $113,708,000 after purchasing an additional 59,620 shares in the last quarter. Commodore Capital LP lifted its position in shares of Nuvalent by 1.8% during the 3rd quarter. Commodore Capital LP now owns 1,400,000 shares of the company’s stock worth $121,072,000 after buying an additional 25,000 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new position in shares of Nuvalent in the 3rd quarter valued at $107,794,000. Institutional investors and hedge funds own 97.26% of the company’s stock.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Stifel Nicolaus increased their price objective on Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Leerink Partners increased their price target on Nuvalent from $140.00 to $149.00 and gave the company an “outperform” rating in a research report on Monday, November 17th. Wedbush reissued an “outperform” rating and set a $125.00 price objective (up from $120.00) on shares of Nuvalent in a research report on Monday, November 17th. JPMorgan Chase & Co. cut their target price on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Finally, HC Wainwright lifted their price target on shares of Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Fifteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $138.33.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.